Literature DB >> 23665307

MicroRNA regulation of endothelial homeostasis and commitment-implications for vascular regeneration strategies using stem cell therapies.

Elizabeth Scott1, Komal Loya, Joanne Mountford, Graeme Milligan, Andrew H Baker.   

Abstract

Human embryonic (hESC) and induced pluripotent (hiPSC) stem cells have broad therapeutic potential in the treatment of a range of diseases, including those of the vascular system. Both hESCs and hiPSCs have the capacity for indefinite self-renewal, in addition to their ability to differentiate into any adult cell type. These cells could provide a potentially unlimited source of cells for transplantation and, therefore, provide novel treatments, e.g. in the production of endothelial cells for vascular regeneration. MicroRNAs are short, noncoding RNAs that act posttranscriptionally to control gene expression and thereby exert influence over a wide range of cellular processes, including maintenance of pluripotency and differentiation. Expression patterns of these small RNAs are tissue specific, and changes in microRNA levels have often been associated with disease states in humans, including vascular pathologies. Here, we review the roles of microRNAs in endothelial cell function and vascular disease, as well as their role in the differentiation of pluripotent stem cells to the vascular endothelial lineage. Furthermore, we discuss the therapeutic potential of stem cells and how knowledge and manipulation of microRNAs in stem cells may enhance their capacity for vascular regeneration.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CVD; EC; EPC; Embryonic stem cells; Free radicals; Induced pluripotent stem cells; MicroRNA; Pluripotency; ROS; Regenerative medicine; VEGF; Vascular endothelial cells; cardiovascular disease; endothelial cell; endothelial progenitor cell; hESC; human embryonic stem cell; iPSC; induced pluripotent stem cell; mESC; miRNA; microRNA; murine embryonic stem cell; reactive oxygen species; vascular endothelial growth factor

Mesh:

Substances:

Year:  2013        PMID: 23665307     DOI: 10.1016/j.freeradbiomed.2013.04.037

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  3 in total

Review 1.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

2.  MiR-92a regulates endothelial progenitor cells (EPCs) by targeting GDF11 via activate SMAD2/3/FAK/Akt/eNOS pathway.

Authors:  Hai-Tao Huang; Zhen-Chuan Liu; Kai-Qin Wu; Shao-Rui Gu; Tian-Cheng Lu; Chong-Jun Zhong; Yong-Xin Zhou
Journal:  Ann Transl Med       Date:  2019-10

3.  Alginate oligosaccharide indirectly affects toll-like receptor signaling via the inhibition of microRNA-29b in aneurysm patients after endovascular aortic repair.

Authors:  Yong Yang; Zhenhuan Ma; Guokai Yang; Jia Wan; Guojian Li; Lingjuan Du; Ping Lu
Journal:  Drug Des Devel Ther       Date:  2017-09-01       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.